Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01217177
Other study ID # CRAD001C24128
Secondary ID
Status Completed
Phase Phase 1
First received October 6, 2010
Last updated April 1, 2015
Start date December 2011
Est. completion date April 2014

Study information

Verified date April 2015
Source Novartis
Contact n/a
Is FDA regulated No
Health authority Brazil: National Health Surveillance AgencyBrazil: ANVISA (Angência Nacional Vigilãncia Sanitária)
Study type Interventional

Clinical Trial Summary

The cervix cancer is the second malignant neoplasia more common between women. The combined treatment involving chemotherapy and radiotherapy was defined as the standard. This study will evaluate the safety, toxicity and maximal tolerated dose (MTD) of everolimus in association with cisplatin and pelvic radiotherapy, in patients with squamous cells carcinoma of uterine cervix, in stages IIB and IIIB.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

1. ECOG performance of 0, 1 or 2.

2. Evidence of measurable disease of unidimensional form.

3. Epidermoid carcinoma confirmed by histological examination of cervix, stages IIB to IIIB (according to clinical and radiological evaluation), without previous treatment. Absence of positive paraaortic lymph nodes at PET (Positron Emission Tomography).

4. Adequate function of organ, according to following criteria:

1. Serum levels of aspartate aminotransferase (ASAT/AAT/AST) and alanine aminotransferase (ALT) =2.5 x ULN (Upper Limit of Normal)

2. Total serum bilirubin =1.5 ULN

3. Absolute neutrophils counting =1.500/mm3

4. Platelet counting =100.000/mm3

5. Hemoglobin =10.0 g/dL

6. Serum calcium =12.0 mg/dL

7. Serum creatinine =1.5 x ULN and estimate creatinine clearance (Cockroft-Gault) =60 mL/min

8. Prothrombin time =1.5 x ULN Obs.: The serum levels of potassium, magnesium, sodium and calcium outside normality range should be corrected before the administration of the first dose of investigational product.

5. Patients with at least one measurable lesion in the baseline period, according to criteria RECIST, version 1.1.

6. Adequate lipid profile: total cholesterol <300 mg/dL and triglycerides <200 mg/dL.

7. Willingness to follow the treatment plan, scheduled visits, laboratory and radiological examinations, as well as other procedures.

8. Signed and dated informed consent form, indicating that the patient (or his/her representative) has received information about all relevant study aspects, before his/her inclusion.

Women with possibility to become pregnant should present a negative serum examination for pregnancy, done within the period of 7 days before the administration of study treatment; and should be willing to use a contraceptive method along the entire study, and for 3 months after the last administration of investigational drug.

Exclusion Criteria:

1. Major surgery <4 weeks before study treatment starting.

2. Any malignant neoplasia in the last 5 years, except for adequately treated melanoma skin cancer.

3. Metastases in the initial diagnostic evaluation [thorax and abdomen computerized tomography (with contrast), pelvis magnetic resonance and PET scanning].

4. Occurrence of some of the following events, during the period of 12 months previously to study medication administration: unstable angina pectoris, symptomatic congestive heart failure (II, III, IV of NYHA), myocardium infarction, severe uncontrolled cardiac arrhythmia, cerebrovascular accident.

5. Positive serology for HIV infection.

6. Patients with positive examinations for hepatitis B (HBsAg, anti-HBs without previous vaccination against HBV and anti-HBc) and hepatitis C (HCV RNA detectable by PCR).

7. Any psychologic, familial, social or geographic problem that could embarrass the adhesion to protocol and study scheme.

8. Patients using other agents under investigation or receiving investigational medications =4 weeks before the study treatment starting.

9. Patients presenting some severe and/or uncontrolled medical problem, or other disturbances that could affect their participation in the study, such as, for instance:

- Unstable angina pectoris, symptomatic congestive heart failure (II, III, IV of NYHA), myocardial infarction =12 months before the first administration of study medication, severe uncontrolled cardiac arrhythmia, cerebrovascular accident =12 months before the starting of study medication administration;

- Severely compromised pulmonary function defined by spirometry with 50% of anticipated normal value or decompensated pulmonary disease.

- Uncontrolled diabetes satisfactorily defined by a fast glycemia result >2.0 x ULN;

- Any active or uncontrolled disease/infection (acute or chronic) compromising the patient evaluation capability or impeding him/her to complete the study.

- Hepatic disease with cirrhosis, decompensated hepatic disease, active chronic hepatitis, or persistent chronic hepatitis.

- Compromising of gastrointestinal (GI) function, or GI disease that could significantly alter the everolimus absorption.

10. Patients unwilling or unable to accomplish the protocol requirements.

11. Hypersensitivity to everolimus or any of its excipients, or to other rapamycins (for instance: sirolimus, temsirolimus).

12. Patients receiving systemic immunosuppressive agents chronically. Inhaling or topic corticosteroids are acceptable. The patients should be receiving stable chronic (not increased within the last month) doses of corticosteroids, with the maximal dose corresponding to 20 mg de prednisone or 10 mg of dexamethasone per day.

Pregnant (that is, having positive examination for beta human chorionic gonadotropin) or lactating women.

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
everolimus


Locations

Country Name City State
Brazil Novartis Investigative Site Rio de Janeiro RJ
Brazil Novartis Investigative Site Rio de Janeiro

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary The toxicity criteria will be evaluated according to National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 3.0. 12 month Yes
Secondary The objective response rate will be evaluated according to clinical/gynecological examination and inconformity with the RECIST criteria (Response Evaluation Criteria in Solid Tumors, version 1.1) 12 month No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03225443 - Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy N/A
Recruiting NCT06079671 - Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Phase 3
Completed NCT05059119 - Rectovaginal Fistula in Post-Radiotherapy Advanced Cervical Cancer Patients
Recruiting NCT06055738 - Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC Phase 2
Recruiting NCT06156514 - Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer Phase 3
Completed NCT03298893 - Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months Phase 1/Phase 2
Withdrawn NCT01514955 - An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer Phase 1
Recruiting NCT05950087 - Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Recruiting NCT04884906 - Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer Phase 2
Not yet recruiting NCT05799469 - Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT05311566 - PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Phase 2
Terminated NCT02045433 - Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT06237257 - A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer Phase 2
Not yet recruiting NCT06288360 - Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Phase 2
Not yet recruiting NCT06288373 - Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Phase 2/Phase 3
Recruiting NCT06068387 - A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis N/A
Recruiting NCT05378087 - Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer N/A
Recruiting NCT03963882 - NAC Followed by RH for the Treatment of LACC Phase 2
Recruiting NCT01938105 - Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer Phase 2
Active, not recruiting NCT01793701 - Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer Phase 1/Phase 2